Abstract
We are issuing this call-to-action to the diabetes community (health care providers [HCPs], people with type 1 diabetes [PwT1D] and their caregivers, and payers) to fully recognize and implement the advances made over the last 10+ years in automated insulin delivery (AID) systems. Pivotal trials and real-world data provide robust and compelling evidence for the benefits of using AID systems, going beyond those of continuous glucose monitors (CGM) when added to a regimen of multiple daily insulin (MDI) injections and/or conventional pump therapy (with or without concomitant CGM).